Search





Search





Markets
/
Stocks
/
nasdaq-ilmn
/

Illumina Inc

ILMN

Add to Watchlist

145.280USD

-0.420-0.29%

Market hours （ET）Quotes delayed by 15 min

22.08BMarket Cap

26.24P/E TTM



Illumina Inc

145.280

-0.420-0.29%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Illumina Inc

Currency: USD Updated: 2026-05-12

Key Insights

Illumina Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 141.20.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Illumina Inc's Score

Industry at a Glance

Industry Ranking

10 / 206

Overall Ranking

78 / 4490

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Illumina Inc Highlights

StrengthsRisks

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 26.32, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 162.52M shares, decreasing 8.64% quarter-over-quarter.

Held by Barrow Hanley

Star Investor Barrow Hanley holds 1.41K shares of this stock.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

141.197

Target Price

-0.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-12

The current financial score of Illumina Inc is 7.04, ranking 91 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 1.09B, representing a year-over-year increase of 4.80%, while its net profit experienced a year-over-year increase of 2.29%.

Score

Industry at a Glance

Previous score

7.04

Change



Financials

7.90

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.85

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.36

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.03

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

6.05

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Illumina Inc's Company Valuation

Currency: USD Updated: 2026-05-12

The current valuation score of Illumina Inc is 8.76, ranking 9 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 26.32, which is 30.45% below the recent high of 34.33 and 173.97% above the recent low of -19.47.

Score

Industry at a Glance

Previous score

8.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/206

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-12

The current earnings forecast score of Illumina Inc is 7.14, ranking 150 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 120.00, with a high of 195.00 and a low of 80.00.

Score

Industry at a Glance

Previous score

7.14

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

141.197

Target Price

-0.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Illumina Inc

ILMN

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-12

The current price momentum score of Illumina Inc is 9.45, ranking 11 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 155.25 and the support level at 127.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.31

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

2.820

Buy

RSI(14)

65.812

Neutral

STOCH(KDJ)(9,3,3)

92.978

Overbought

ATR(14)

6.194

Low Volatility

CCI(14)

107.854

Buy

Williams %R

3.803

Overbought

TRIX(12,20)

0.429

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

142.276

Buy

MA10

137.271

Buy

MA20

133.814

Buy

MA50

128.090

Buy

MA100

131.610

Buy

MA200

119.434

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Illumina Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 107.41%, representing a quarter-over-quarter increase of 1.86%. The largest institutional shareholder is PRIMECAP Management, holding a total of 1.99M shares, representing 1.32% of shares outstanding, with 12.20% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

20.10M

+0.62%

BlackRock Institutional Trust Company, N.A.

13.15M

+0.07%

State Street Investment Management (US)

6.19M

+3.17%

WCM Investment Management

4.07M

-2.64%

AQR Capital Management, LLC

4.43M

+30.26%

Loomis, Sayles & Company, L.P.

4.17M

-2.70%

Corvex Management LP

3.83M

Sessa Capital

3.40M

-27.37%

Risk Assessment

Currency: USD Updated: 2026-05-12

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Illumina Inc is 6.49, ranking 57 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.